Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs)

被引：21

作者：

Mercer, Swati P. ^{[1
]}

Roecker, Anthony J. ^{[1
]}

Garson, Susan ^{[2
]}

Reiss, Duane R. ^{[2
]}

Harrell, C. Meacham ^{[2
]}

Murphy, Kathy L. ^{[2
]}

Bruno, Joseph G. ^{[4
]}

Bednar, Rodney A. ^{[4
]}

Lemaire, Wei ^{[2
]}

Cui, Donghui ^{[3
]}

Cabalu, Tamara D. ^{[3
]}

Tang, Cuyue ^{[3
]}

Prueksaritanont, Thomayant ^{[3
]}

Hartman, George D. ^{[1
]}

Young, Steven D. ^{[1
]}

Winrow, Christopher J. ^{[2
]}

Renger, John J. ^{[2
]}

Coleman, Paul J. ^{[1
]}

机构：

[1] Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA

[2] Merck Res Labs, Dept Neurosci, West Point, PA 19486 USA

[3] Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA

[4] Merck Res Labs, West Point Facil Automat & Screening WP FAST, West Point, PA 19486 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 24期

关键词：

Orexin receptor antagonists; Selective orexin-2 receptor antagonists; Insomnia; Hypocretin; Rat sleep EEG; P-GLYCOPROTEIN; POTENT; SLEEP; PROMOTION;

D O I：

10.1016/j.bmcl.2013.10.045

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The orexin (or hypocretin) system has been identified as a novel target for the treatment of insomnia due to the wealth of biological and genetic data discovered over the past decade. Recently, clinical proof-of-concept was achieved for the treatment of primary insomnia using dual (OX1R/OX2R) orexin receptor antagonists. However, elucidation of the pharmacology associated with selective orexin-2 receptor antagonists (2-SORAs) has been hampered by the lack of orally bioavailable, highly selective small molecule probes. Herein, the discovery and optimization of a novel series of 2,5-diarylnicotinamides as potent and orally bioavailable orexin-2 receptor selective antagonists is described. A compound from this series demonstrated potent sleep promotion when dosed orally to EEG telemetrized rats. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：6620 / 6624

页数：5

共 50 条

[21] Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands
Mould, R.
Brown, J.
Marshall, F. H.
Langmead, C. J.
BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (02) : 351 - 363
[22] Protein distribution of the orexin-2 receptor in the rat central nervous system
Cluderay, JE
Harrison, DC
Hervieu, GJ
REGULATORY PEPTIDES, 2002, 104 (1-3) : 131 - 144
[23] Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement
James R. Shoblock
Natalie Welty
Leah Aluisio
Ian Fraser
S. Timothy Motley
Kirsten Morton
James Palmer
Pascal Bonaventure
Nicholas I. Carruthers
Timothy W. Lovenberg
Jamin Boggs
Ruggero Galici
Psychopharmacology, 2011, 215 : 191 - 203
[24] Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models
Anderson, Rachel I.
Becker, Howard C.
Adams, Benjamin L.
Jesudason, Cynthia D.
Rorick-Kehn, Linda M.
FRONTIERS IN NEUROSCIENCE, 2014, 8
[25] Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleep
Kummangal, Basheer Ahamad
Kumar, Deependra
Mallick, Hruda Nanda
BEHAVIOURAL BRAIN RESEARCH, 2013, 237 : 59 - 62
[26] Orexin-2 receptor selective agonist, [Ala11]orexin-B promotes wakefulness in freely behaving rats
Honda, K
Akanmu, MA
Asahi, S
Egashira, S
Ihara, M
SLEEP, 2003, 26 : A15 - A16
[27] Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia
Bonaventure, Pascal
Shelton, Jonathan
Yun, Sujin
Nepomuceno, Diane
Sutton, Steven
Aluisio, Leah
Fraser, Ian
Lord, Brian
Shoblock, James
Welty, Natalie
Chaplan, Sandra R.
Aguilar, Zuleima
Halter, Robin
Ndifor, Anthony
Koudriakova, Tatiana
Rizzolio, Michele
Letavic, Michael
Carruthers, Nicholas I.
Lovenberg, Timothy
Dugovic, Christine
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2015, 354 (03): : 471 - 482
[28] Development of an orexin-2 receptor selective agonist, [Ala11, D-Leu15]orexin-B
Asahi, S
Egashira, SI
Matsuda, M
Iwaasa, H
Kanatani, A
Ohkubo, M
Ihara, M
Morishima, H
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (01) : 111 - 113
[29] Narcoleptic behavioral arrests in orexin ligand and orexin-2 receptor knockout mice are neurophysiologically distinct
Willie, JT
Sinton, CM
Yanagisawa, M
Chemelli, RM
SLEEP, 2001, 24 : A24 - A24
[30] Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement
Shoblock, James R.
Welty, Natalie
Aluisio, Leah
Fraser, Ian
Motley, S. Timothy
Morton, Kirsten
Palmer, James
Bonaventure, Pascal
Carruthers, Nicholas I.
Lovenberg, Timothy W.
Boggs, Jamin
Galici, Ruggero
PSYCHOPHARMACOLOGY, 2011, 215 (01) : 191 - 203

← 1 2 3 4 5 →